南华生物(000504) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥22,453,576.28, a decrease of 13.55% compared to ¥25,973,854.69 in the same period last year[5] - The net loss attributable to shareholders was ¥2,218,632.26, an improvement of 19.92% from a loss of ¥2,770,653.53 in the previous year[5] - Net profit for the current period is -¥6,522,060.18, compared to -¥2,846,531.87 in the previous period, indicating a significant increase in losses[19] - Total operating revenue for the current period is ¥22,453,576.28, a decrease of 13.7% from ¥25,973,854.69 in the previous period[18] - Total operating costs increased to ¥30,056,727.81, up 0.3% from ¥29,981,563.79 in the previous period[18] - The total comprehensive income for the current period is -¥6,522,060.18, compared to -¥2,846,531.87 in the previous period[19] Cash Flow and Liquidity - The net cash flow from operating activities improved by 45.15%, reaching -¥825,292.27 compared to -¥1,504,744.35 in the prior year[5] - Operating cash flow for the current period is -¥825,292.27, an improvement from -¥1,504,744.35 in the previous period[21] - Cash and cash equivalents at the end of the period decreased to ¥141,375,896.11 from ¥212,597,686.65 in the previous period[22] - The company's cash and cash equivalents decreased by 31.81% to ¥141,405,896.11, primarily due to investments in bank wealth management products[8] - Investment activities generated a net cash outflow of -¥63,643,586.86, compared to -¥118,821,316.99 in the previous period, indicating reduced cash outflow[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥601,914,862.34, a decrease of 1.03% from ¥608,169,817.97 at the end of the previous year[5] - Current assets decreased to CNY 389,870,377.50 from CNY 401,904,309.43, primarily due to a reduction in cash and cash equivalents[15] - The company's inventory decreased by 35.74% to ¥21,886,655.45, mainly due to reduced stock levels at subsidiaries[8] - Accounts receivable decreased from CNY 139,581,939.21 to CNY 124,633,751.11, a reduction of approximately 10.7%[15] - Total liabilities remained relatively stable, with a slight increase from CNY 326,171,710.73 to CNY 326,671,985.01[16] - The company's total equity decreased from CNY 281,998,107.24 to CNY 275,242,877.33, indicating a decline of about 2.7%[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,992[11] - The largest shareholder, Hunan Caixin Industrial Fund Management Co., Ltd., holds 29.74% of the shares, totaling 98,150,852 shares[11] Earnings Per Share - The company's basic and diluted earnings per share improved to -¥0.0067, a 20.24% increase from -¥0.0084 in the same period last year[5] - The basic and diluted earnings per share for the current period are both -¥0.0067, compared to -¥0.0084 in the previous period[19] Research and Development - The company reported a significant increase in research and development expenses to ¥2,816,476.66, up from ¥2,184,441.44 in the previous period[18] Audit Status - The company has not undergone an audit for the first quarter report[23]